Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Wave Life Sciences

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities1.10%
Size of stake in company2.60%
Market capitalizationUSD 1.2 bn

Sector

Genetic Medicines

Main candidate

WVE-006, WVE-N531

Main indications

Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy

About the company

Wave Life Sciences is a clinical-stage company focused on developing oligonucleotide-based therapeutics for devastating rare diseases. Wave Life Sciences’ proprietary discovery and drug development platform, PRISM, enables the precise design, optimization, and production of novel stereo-pure oligonucleotides across multiple therapeutic modalities, including RNA editing, splicing, and silencing. WVE’s current drug candidates include WVE-006 (RNA editing for alpha-1-antitrypsin deficiency), WVE-N531 (exon 53 skipper for Duchenne muscular dystrophy), WVE-003 (antisense oligonucleotide selective for mutant huntingtin in Huntington’s disease) and a new candidate targeting INHBE to treat metabolic disorders including obesity.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.